Professor
Director, Centre for Pharmaceutical Oncology
Molecular Imaging and Targeted Radiotherapy of Cancer
Our research focuses on the discovery, preclinical development and translation to Phase I/II clinical trials of novel radiopharmaceuticals for molecular imaging and targeted radiotherapy of cancer.
Molecular Imaging is a powerful new imaging modality which probes the biology of tumours to permit their detection, but most importantly reveal their phenotypic properties. Molecular imaging which includes SPECT and PET nuclear medicine technologies has great potential for cancer detection as well as predicting and monitoring response to treatment, especially to new molecularly-targeted drugs (e.g. Herceptin). Our approach focuses on imaging the over expression of peptide growth factor receptors (e.g. EGFR, HER2 or IGF-1R) since these are often the targets for these drugs. In addition, we are interested in imaging leukemia stem cells using radiolabeled anti-CD123 antibodies; imaging of cytolytic vaccinia virus delivery to tumours using radiolabeled octreotide analogues, and imaging the tumour and normal tissue distribution of micellar drug delivery systems. In addition, we are conducting a Phase I/II clinical trial of radioimmunoguided surgery (RIGS) of breast cancer using radiolabeled trastuzumab Fab antibodies directed against HER2 which aims to improve the surgical management of the disease.
Read more at http://www.pharmacy.utoronto.ca/users/reillyra
Area(s) of interest in Pharmaceutical Oncology:
- Cancer biology
- Cancer genomics/genetics
- Animal models
- Cancer target discovery
- Synthesis of anti-cancer agents
- Antibody Engineering 3
- Polymer chemistry
- Nanomedicines
- Pharmacokinetics
- Imaging
- Radiation medicine
- Surgical oncology
- Formulation science
- Toxicology
- Clinical trials
- Experimental therapeutics
- Immunotherapy
- Cancer stem cells
- Phototherapy
- Patient care
- Health economics
- Public policy
- Continuing Education
- Other
Trainees within CPO:
- Smith, Joe
- Zed, Fred
